Table 2.

Analysis and prognostic value of TGIF expression overall and in patient subgroups

Analysis	Parameter	DFS			OS
		HRa (95%CI)	Log-rank p-value	Bivariate interaction p-value	HRa (95%CI)	Log-rank p-value	Bivariate interaction p-value
Overall
	TGIF moderate/strong	0.75 (0.59–0.95)	0.019	–	0.69 (0.51–0.94)	0.018	–
Subgroups
iddEPC	moderate/strong TGIF	0.70 (0.50–0.98)	0.036	0.575	0.69 (0.45–1.07)	0.095	0.978
ddEC-PwX	moderate/strong TGIF	0.81 (0.58–1.14)	0.228		0.69 (0.45–1.08)	0.105
Ibandronate treatment	moderate/strong TGIF	0.79 (0.59–1.07)	0.131	0.620	0.72 (0.49–1.06)	0.094	0.729
without Ibandronate treatment	moderate/strong TGIF	0.68 (0.46–1.01)	0.057		0.64 (0.38–1.07)	0.087
ER-negative	moderate/strong TGIF	1.03 (0.67–1.58)	0.893	0.130	1.02 (0.60–1.75)	0.933	0.107
ER-positive	moderate/strong TGIF	0.68 (0.51–0.91)	0.009		0.60 (0.41–0.88)	0.008
HER2-negative	moderate/strong TGIF	0.67 (0.50–0.88)	0.004	0.034	0.57 (0.40–0.82)	0.002	0.015
HER2-positive	moderate/strong TGIF	1.27 (0.75–2.18)	0.375		1.79 (0.80–4.00)	0.151
TNBC	moderate/strong TGIF	1.00 (0.57–1.75)	0.995	0.427	1.05 (0.56–1.96)	0.876	0.291
non-TNBC	moderate/strong TGIF	0.76 (0.58–1.00)	0.049		0.70 (0.48–1.01)	0.055

^anegative/low TGIF expression is reference

Prognostic value of TGIF for TTPBM, overall: HR = 0.77 (95%CI 0.51–1.16); p = 0.213. Of note, the TTPBM analysis in subgroups is not presented due to the small number of bone metastases occurred as first event

HER2 human epidermal growth factor receptor 2, ER estrogen receptor, PR progesterone receptor, iddEPC intense dose-dense epirubicin plus paclitaxel plus cyclophosphamide, ddEC-PwX dose-dense epirubicin plus cyclophosphamide plus paclitaxel weekly and capecitabine, TNBC triple-negative breast cancer, HR hazard ratio, DFS disease-free survival, OS overall survival, CI confidence interval, TTPBM time to primary bone metastasis